Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Pricing Clinical Trials Drug Safety Weight Loss Weight Loss Drugs Cancer Treatment Drug Regulation Medications

FDA Approves Vanda’s Nereus to Prevent Motion-Induced Vomiting

The decision delivers the first pharmacologic therapy for motion sickness in more than 40 years.

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation With April 30, 2026 Decision Target

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers